John R Perfect

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6578919/publications.pdf

Version: 2024-02-01

253 papers	24,601 citations	14655 66 h-index	8167 148 g-index
280 all docs	280 docs citations	280 times ranked	18874 citing authors

#	Article	IF	Citations
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	5.8	4,375
2	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2010, 50, 291-322.	5.8	2,195
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
4	Human Dectin-1 Deficiency and Mucocutaneous Fungal Infections. New England Journal of Medicine, 2009, 361, 1760-1767.	27.0	671
5	Voriconazole Treatment for Lessâ€Common, Emerging, or Refractory Fungal Infections. Clinical Infectious Diseases, 2003, 36, 1122-1131.	5.8	643
6	Cryptococcus neoformans. , 1998, , .		642
7	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	9.1	586
8	The antifungal pipeline: a reality check. Nature Reviews Drug Discovery, 2017, 16, 603-616.	46.4	574
9	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infectious Diseases, The, 2016, 16, 828-837.	9.1	528
10	Combination Antifungal Therapy. Antimicrobial Agents and Chemotherapy, 2004, 48, 693-715.	3.2	478
11	Resistance to Antifungal Agents: Mechanisms and Clinical Impact. Clinical Infectious Diseases, 2008, 46, 120-128.	5.8	473
12	Cryptococcosis. Infectious Disease Clinics of North America, 2016, 30, 179-206.	5.1	473
13	Urease as a Virulence Factor in Experimental Cryptococcosis. Infection and Immunity, 2000, 68, 443-448.	2.2	459
14	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases, 2008, 47, 674-683.	5.8	368
15	Cryptococcosis. Infectious Disease Clinics of North America, 2002, 16, 837-874.	5.1	354
16	Analysis of the Genome and Transcriptome of Cryptococcus neoformans var. grubii Reveals Complex RNA Expression and Microevolution Leading to Virulence Attenuation. PLoS Genetics, 2014, 10, e1004261.	3.5	336
17	Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Molecular Microbiology, 2001, 39, 166-175.	2.5	319
18	Cyclic AMP-Dependent Protein Kinase Controls Virulence of the Fungal Pathogen Cryptococcus neoformans. Molecular and Cellular Biology, 2001, 21, 3179-3191.	2.3	310

#	Article	IF	Citations
19	The Case for Adopting the â€œSpecies Complexâ€•Nomenclature for the Etiologic Agents of Cryptococcosis. MSphere, 2017, 2, .	2.9	274
20	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	7.3	255
21	Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2005, 49, 952-958.	3.2	212
22	RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Molecular Microbiology, 2000, 36, 352-365.	2.5	211
23	Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genetics and Biology, 2015, 78, 49-54.	2.1	194
24	CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. Journal of Clinical Investigation, 2013, 123, 5035-5051.	8.2	190
25	Azole antifungals: 35 years of invasive fungal infection management. Expert Review of Anti-Infective Therapy, 2015, 13, 787-798.	4.4	179
26	Morphologic Criteria for the Preliminary Identification ofFusarium, Paecilomyces, andAcremoniumSpecies by Histopathology. American Journal of Clinical Pathology, 1998, 109, 45-54.	0.7	177
27	Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clinical Infectious Diseases, 2016, 63, 356-362.	5.8	167
28	Comparison and Temporal Trends of Three Groups with Cryptococcosis: HIV-Infected, Solid Organ Transplant, and HIV-Negative/Non-Transplant. PLoS ONE, 2012, 7, e43582.	2.5	161
29	Protection against Cryptococcosis by Using a Murine Gamma Interferon-Producing Cryptococcus neoformans Strain. Infection and Immunity, 2007, 75, 1453-1462.	2.2	160
30	Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, inCryptococcus neoformans. EMBO Journal, 2000, 19, 3618-3629.	7.8	158
31	Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nature Communications, 2013, 4, 1342.	12.8	157
32	Fungi that Infect Humans. Microbiology Spectrum, 2017, 5, .	3.0	149
33	Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Molecular Microbiology, 2008, 69, 1456-1475.	2.5	147
34	Plasminogen Alleles Influence Susceptibility to Invasive Aspergillosis. PLoS Genetics, 2008, 4, e1000101.	3.5	145
35	Characterization and Regulation of the Trehalose Synthesis Pathway and Its Importance in the Pathogenicity of Cryptococcus neoformans. Infection and Immunity, 2006, 74, 5877-5887.	2.2	144
36	Treatment of Non-Aspergillus Moulds in Immunocompromised Patients, with Amphotericin B Lipid Complex. Clinical Infectious Diseases, 2005, 40, S401-S408.	5.8	142

#	Article	IF	Citations
37	Antifungal Resistance Trends Towards the Year 2000. Drugs, 1997, 54, 657-678.	10.9	140
38	The STE12Î± Homolog Is Required for Haploid Filamentation But Largely Dispensable for Mating and Virulence in Cryptococcus neoformans. Genetics, 1999, 153, 1601-1615.	2.9	138
39	ECMM/ISHAM recommendations for clinical management of COVIDâ€19 associated mucormycosis in lowâ€• and middleâ€•income countries. Mycoses, 2021, 64, 1028-1037.	4.0	137
40	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. Journal of Infectious Diseases, 2017, 216, S474-S483.	4.0	135
41	Population genomics and the evolution of virulence in the fungal pathogen Cryptococcus neoformans. Genome Research, 2017, 27, 1207-1219.	5.5	134
42	Titan cells formation in Cryptococcus neoformans is finely tuned by environmental conditions and modulated by positive and negative genetic regulators. PLoS Pathogens, 2018, 14, e1006982.	4.7	119
43	Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia. Journal of Infectious Diseases, 2012, 205, 934-943.	4.0	116
44	The Cryptococcus neoformans Transcriptome at the Site of Human Meningitis. MBio, 2014, 5, e01087-13.	4.1	113
45	Tracing Genetic Exchange and Biogeography of Cryptococcus neoformans var. grubii at the Global Population Level. Genetics, 2017, 207, 327-346.	2.9	105
46	Trehalose 6â€•phosphate phosphatase is required for cell wall integrity and fungal virulence but not trehalose biosynthesis in the human fungal pathogen Aspergillus fumigatus. Molecular Microbiology, 2010, 77, 891-911.	2.5	104
47	Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia. Antimicrobial Agents and Chemotherapy, 2014, 58, 5758-5765.	3.2	99
48	Drug resistance in Cryptococcus neoformans. Drug Resistance Updates, 1999, 2, 259-269.	14.4	95
49	Intracellular Action of a Secreted Peptide Required for Fungal Virulence. Cell Host and Microbe, 2016, 19, 849-864.	11.0	93
50	Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development. Microbiology and Molecular Biology Reviews, 2017, 81, .	6.6	93
51	Cryptococcus neoformans: A sugar-coated killer with designer genes. FEMS Immunology and Medical Microbiology, 2005, 45, 395-404.	2.7	92
52	In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	90
53	Cryptococcus neoformans Requires a Functional Glycolytic Pathway for Disease but Not Persistence in the Host. MBio, 2011, 2, e00103-11.	4.1	89
54	The Trehalose Synthesis Pathway Is an Integral Part of the Virulence Composite for Cryptococcus gattii. Infection and Immunity, 2009, 77, 4584-4596.	2.2	88

#	Article	IF	Citations
55	Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. Molecular Microbiology, 2001, 40, 610-620.	2.5	86
56	Fungal diagnosis: how do we do it and can we do better?. Current Medical Research and Opinion, 2013, 29, 3-11.	1.9	83
57	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. Journal of Infectious Diseases, 2020, 222, S175-S198.	4.0	83
58	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
59	Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. Clinical Infectious Diseases, 2020, 70, 30-39.	5.8	79
60	Use of Antifungal Combination Therapy: Agents, Order, and Timing. Current Fungal Infection Reports, 2010, 4, 87-95.	2.6	76
61	The Impact of the Host on Fungal Infections. American Journal of Medicine, 2012, 125, S39-S51.	1.5	76
62	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	12.8	76
63	Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections. Annals of Internal Medicine, 2019, 170, 845.	3.9	72
64	CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. Science Translational Medicine, 2016, 8, 322ra10.	12.4	71
65	Topoisomerase I Is Essential in Cryptococcus neoformans: Role in Pathobiology and as an Antifungal Target. Genetics, 1999, 152, 167-178.	2.9	71
66	Brain Inositol Is a Novel Stimulator for Promoting Cryptococcus Penetration of the Blood-Brain Barrier. PLoS Pathogens, 2013, 9, e1003247.	4.7	69
67	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 963-974.	2.9	69
68	Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C.Âgattii. MBio, 2017, 8, .	4.1	69
69	Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. Clinical Infectious Diseases, 2012, 54, 502-510.	5.8	68
70	â€œIs there an emerging need for new antifungals?â€• Expert Opinion on Emerging Drugs, 2016, 21, 129-131.	2.4	68
71	Live Imaging of Host-Parasite Interactions in a Zebrafish Infection Model Reveals Cryptococcal Determinants of Virulence and Central Nervous System Invasion. MBio, 2015, 6, e01425-15.	4.1	65
72	Association of Plasma Levels of Human Immunodeficiency Virus Type 1 RNA and OropharyngealCandidaColonization. Journal of Infectious Diseases, 1999, 180, 534-537.	4.0	62

#	Article	IF	Citations
73	Comparative analyses of clinical and environmental populations of <scp>C</scp>ryptococcus neoformans in <scp>B</scp>otswana. Molecular Ecology, 2015, 24, 3559-3571.	3.9	61
74	Adverse Drug Reactions to Systemic Antifungals Prevention and Management. Drug Safety, 1992, 7, 323-363.	3.2	60
75	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, 2021, 184, 2955-2972.e25.	28.9	57
76	Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans. PLoS ONE, 2013, 8, e57672.	2.5	54
77	Update on Epidemiology of and Preventive Strategies for Invasive Fungal Infections in Cancer Patients. Clinical Infectious Diseases, 2014, 59, S352-S355.	5.8	54
78	The war on cryptococcosis: A Review of the antifungal arsenal. Memorias Do Instituto Oswaldo Cruz, 2018, 113, e170391.	1.6	54
79	Trehalose pathway as an antifungal target. Virulence, 2017, 8, 143-149.	4.4	53
80	A global call for talaromycosis to be recognised as a neglected tropical disease. The Lancet Global Health, 2021, 9, e1618-e1622.	6.3	52
81	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. Clinical Infectious Diseases, 2021, 72, 1268-1278.	5.8	51
82	Phenotypic Variability Correlates with Clinical Outcome in Cryptococcus Isolates Obtained from Botswanan HIV/AIDS Patients. MBio, 2018, 9, .	4.1	50
83	Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. Expert Opinion on Emerging Drugs, 2011, 16, 559-586.	2.4	48
84	Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infectious Diseases, 2017, 4, ofw261.	0.9	48
85	Survival Defects of Cryptococcus neoformans Mutants Exposed to Human Cerebrospinal Fluid Result in Attenuated Virulence in an Experimental Model of Meningitis. Infection and Immunity, 2010, 78, 4213-4225.	2.2	47
86	Inkjet Printing of Amphotericin B onto Biodegradable Microneedles Using Piezoelectric Inkjet Printing. Jom, 2013, 65, 525-533.	1.9	47
87	Fatty Acid Synthesis Is Essential for Survival of Cryptococcus neoformans and a Potential Fungicidal Target. Antimicrobial Agents and Chemotherapy, 2007, 51, 3537-3545.	3.2	46
88	Present and Future Therapy of Cryptococcus Infections. Journal of Fungi (Basel, Switzerland), 2018, 4, 79.	3.5	46
89	Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7148-7153.	7.1	44
90	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. MBio, 2019, 10, .	4.1	44

#	Article	IF	Citations
91	Antisense repression in Cryptococcus neoformans as a laboratory tool and potential antifungal strategy. Microbiology (United Kingdom), 2002, 148, 213-219.	1.8	44
92	Tolerability profile of the current antifungal armoury. Journal of Antimicrobial Chemotherapy, 2018, 73, i26-i32.	3.0	41
93	Associations between Cryptococcus Genotypes, Phenotypes, and Clinical Parameters of Human Disease: A Review. Journal of Fungi (Basel, Switzerland), 2021, 7, 260.	3.5	41
94	Blood Gene Expression Signatures Predict Invasive Candidiasis. Science Translational Medicine, 2010, 2, 21ra17.	12.4	40
95	Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. Journal of Medical Microbiology, 2018, 67, 215-227.	1.8	38
96	Human genetic susceptibility toCandidainfections. Medical Mycology, 2012, 50, 785-794.	0.7	37
97	Copy number variation contributes to cryptic genetic variation in outbreak lineages of Cryptococcus gattii from the North American Pacific Northwest. BMC Genomics, 2016, 17, 700.	2.8	36
98	Next generation multilocus sequence typing (NGMLST) and the analytical software program MLSTEZ enable efficient, cost-effective, high-throughput, multilocus sequencing typing. Fungal Genetics and Biology, 2015, 75, 64-71.	2.1	34
99	Genetic Susceptibility to Fungal Infections: What is in the Genes?. Current Clinical Microbiology Reports, 2016, 3, 81-91.	3.4	34
100	Genomeâ€wide analysis of the regulation of Cu metabolism in Cryptococcus neoformans. Molecular Microbiology, 2018, 108, 473-494.	2.5	34
101	Surfactant Protein D Facilitates Cryptococcus neoformans Infection. Infection and Immunity, 2012, 80, 2444-2453.	2.2	33
102	Regulation of cytochrome c oxidase subunit 1 (COX1) expression in Cryptococcus neoformans by temperature and host environment. Microbiology (United Kingdom), 2003, 149, 1041-1049.	1.8	33
103	Isavuconazole for treatment of rare invasive fungal diseases. Mycoses, 2018, 61, 518-533.	4.0	32
104	Taming Amphotericin B. Bioconjugate Chemistry, 2015, 26, 2021-2024.	3.6	31
105	Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. PLoS Pathogens, 2019, 15, e1007945.	4.7	31
106	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. Clinical Infectious Diseases, 2019, 68, 850-853.	5.8	31
107	Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis. Clinical Infectious Diseases, 2021, 73, e330-e336.	5.8	29
108	Combination Therapy for Invasive Fungal Infections. Current Fungal Infection Reports, 2020, 14, 40-49.	2.6	29

#	Article	IF	Citations
109	Cryptococcal meningoencephalitis: time for action. Lancet Infectious Diseases, The, 2021, 21, e259-e271.	9.1	29
110	Deferoxamine Treatment as a Risk Factor for Zygomycete Infection. Journal of Infectious Diseases, 1989, 159, 151-152.	4.0	28
111	Design of Aerosolized Amphotericin B Formulations for Prophylaxis Trials among Lung Transplant Recipients. Clinical Infectious Diseases, 2004, 39, S207-S210.	5.8	28
112	The Zinc Finger Protein Mig1 Regulates Mitochondrial Function and Azole Drug Susceptibility in the Pathogenic Fungus Cryptococcus neoformans. MSphere, 2016, 1, .	2.9	28
113	Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. Journal of Infectious Diseases, 2018, 218, 1147-1154.	4.0	28
114	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
115	Amoeba Predation of Cryptococcus neoformans Results in Pleiotropic Changes to Traits Associated with Virulence. MBio, 2021, 12, .	4.1	27
116	Structural and In Vivo Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design. MBio, 2017, 8, .	4.1	26
117	Emerging Issues in Antifungal Resistance. Infectious Disease Clinics of North America, 2020, 34, 921-943.	5.1	26
118	MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections. Clinical Infectious Diseases, 2021, 73, 1133-1141.	5.8	26
119	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the <scp>VITAL</scp> trial. Mycoses, 2018, 61, 420-429.	4.0	25
120	Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil. Emerging Microbes and Infections, 2019, 8, 119-129.	6.5	25
121	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. Open Forum Infectious Diseases, 2022, 9, .	0.9	25
122	Invasive Mycoses: Evolving Challenges and Opportunities in Antifungal Therapy (Multimedia Activity). American Journal of Medicine, 2011, 124, S2-S3.	1.5	24
123	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses, 2018, 61, 485-497.	4.0	24
124	Landscape of gene expression variation of natural isolates of Cryptococcus neoformans in response to biologically relevant stresses. Microbial Genomics, 2020, 6, .	2.0	24
125	An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. PLoS ONE, 2017, 12, e0180824.	2.5	24
126	The Triple Threat of Cryptococcosis: Itâ€™s the Body Site, the Strain, and/or the Host. MBio, 2012, 3, .	4.1	23

#	Article	IF	Citations
127	Gene Expression of Diverse Cryptococcus Isolates during Infection of the Human Central Nervous System. MBio, 2021, 12, e0231321.	4.1	23
128	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opinion on Investigational Drugs, 2022, 31, 795-812.	4.1	23
129	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials, 2015, 16, 276.	1.6	22
130	Repeated therapeutic lumbar punctures in cryptococcal meningitis â€“ necessity and/or opportunity?. Current Opinion in Infectious Diseases, 2016, 29, 539-545.	3.1	21
131	New potential targets for antifungal development. Expert Opinion on Therapeutic Targets, 2000, 4, 265-296.	1.0	20
132	Environmental Niches forCryptococcus neoformansandCryptococcus gattii. , 0, , 235-259.		19
133	Fungal infections of the bones and joints. Current Infectious Disease Reports, 2001, 3, 450-460.	3.0	18
134	Molecular Typing of the Cryptococcus neoformans/Cryptococcus gattii Species Complex. , 2014, , 327-357.		18
135	Cases of disseminated cryptococcosis in intravenous drug abusers without HIV infection: A new risk factor?. Medical Mycology Case Reports, 2016, 14, 17-19.	1.3	18
136	Comparing outcomes of early, late, and non-surgical management of intraspinal abscess. Journal of Clinical Neuroscience, 2017, 36, 64-71.	1.5	17
137	A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. Journal of Infectious Diseases, 2019, 220, 862-872.	4.0	17
138	Clinical Perspectives onCryptococcus neoformansandCryptococcus gattii: Implications for Diagnosis and Management. , 0, , 595-606.		16
139	Cryptococcal Meningitis with Normal Cerebrospinal Fluid. Journal of Infectious Diseases, 1989, 160, 912-912.	4.0	15
140	The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td (m	3.0	14
141	OccultTalaromyces marneffeiInfection Unveiled by the Novel Mp1p Antigen Detection Assay. Open Forum Infectious Diseases, 2020, 7, ofaa502.	0.9	14
142	The virulence factor urease and its unexplored role in the metabolism of Cryptococcus neoformans. FEMS Yeast Research, 2020, 20, .	2.3	13
143	Systematics of the Genus Cryptococcus and Its Type Species C. neoformans. , 0, , 1-15.		12
144	Retrospective review of amphotericin B use in a tertiary-care medical center. American Journal of Health-System Pharmacy, 1987, 44, 1353-1357.	1.0	11

#	Article	IF	Citations
145	Scedosporium apiosermum infection of the â€œNativeâ€•valve: Fungal endocarditis in an orthotopic heart transplant recipient. Medical Mycology Case Reports, 2015, 9, 34-36.	1.3	11
146	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 493-500.	5.8	10
147	Simple Strategy for Taming Membrane-Disrupting Antibiotics. Bioconjugate Chemistry, 2016, 27, 2850-2853.	3.6	10
148	Pulmonary blastomycosis presenting as primary lung cancer. BMC Infectious Diseases, 2018, 18, 336.	2.9	10
149	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
150	A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. Medical Mycology Case Reports, 2020, 27, 17-21.	1.3	10
151	The robust and rapid role of molecular testing in precision fungal diagnostics: A case report. Medical Mycology Case Reports, 2020, 27, 77-80.	1.3	10
152	Veterinary Insights into Cryptococcosis Caused by Cryptococcus neoformans and Cryptococcus gattii. , 0, , 489-504.		10
153	Human Cryptococcosis. , 0, , 407-456.		10
154	Inositol Metabolism Regulates Capsule Structure and Virulence in the Human Pathogen Cryptococcus neoformans. MBio, 2021, 12, e0279021.	4.1	10
155	Management of Cryptococcosis: How Are We Doing?. PLoS Medicine, 2007, 4, e47.	8.4	9
156	Emergence of the Molds Other than Aspergillus in Immunocompromised Patients. Clinics in Chest Medicine, 2017, 38, 555-573.	2.1	9
157	Fungal Molecular Pathogenesis: What Can It Do and Why Do We Need It?. , 0, , 1-11.		9
158	Fungi that Infect Humans. , 2017, , 811-843.		8
159	Regulatory Mechanism of the Atypical AP-1-Like Transcription Factor Yap1 in Cryptococcus neoformans. MSphere, 2019, 4, .	2.9	8
160	Assessing the virulence of Cryptococcus neoformans causing meningitis in HIV infected and uninfected patients in Vietnam. Medical Mycology, 2020, 58, 1149-1161.	0.7	8
161	The Architecture and Antigenic Composition of the Polysaccharide Capsule. , 0, , 43-54.		8
162	Mycobacterium Avium-intracellulare complex infections in the acquired immunodeficiency syndrome. Journal of Electron Microscopy Technique, 1988, 8, 105-113.	1.1	7

#	Article	IF	Citations
163	Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. Journal of Antimicrobial Chemotherapy, 2019, 74, 228-233.	3.0	7
164	Complete Genome Sequences for Two Talaromyces marneffei Clinical Isolates from Northern and Southern Vietnam. Microbiology Resource Announcements, 2020, 9, .	0.6	7
165	Uncommon Yeasts and Molds Causing Human Disease. , 2021, , 813-834.		7
166	The longitudinal health economic impact of viral encephalitis in the United States. Journal of Medical Microbiology, 2020, 69, 270-279.	1.8	7
167	The Mating-Type Locus of Cryptococcus: Evolution of Gene Clusters Governing Sex Determination and Sexual Reproduction from the Phylogenomic Perspective. , 0, , 139-149.		7
168	Potential Value of Cefoperazone in Bacterial Meningitis. Drugs, 1981, 22, 60-64.	10.9	6
169	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	6
170	Comparison of Cryptococcus gattii/neoformans Species Complex to Related Genera (Papiliotrema and) Tj ETQq0 0 0 rgBT /Overlock 10 T in Cellular and Infection Microbiology, 2021, 11, 642658.	3.9	6
171	Cryptococcus neoformans : a Sugar-Coated Killer. , 0, , 279-303.		6
172	Invasion of Cryptococcus into the Central Nervous System. , 0, , 465-471.		6
173	Public Health Importance of Cryptococcal Disease: Epidemiology, Burden, and Control. , 0, , 585-593.		6
174	Diagnosis and Laboratory Techniques. , 0, , 381-405.		6
175	Virulence Factors. , 0, , 145-176.		6
176	Editorial: Antifungal Pipeline: Build It Strong; Build It Better!. Frontiers in Cellular and Infection Microbiology, 2022, 12, 881272.	3.9	6
177	Familial Adenomatous Polyposis Manifesting asLactococcusEndocarditis: A Case Report and Review of the Association ofLactococcuswith Underlying Gastrointestinal Disease. Case Reports in Infectious Diseases, 2016, 2016, 1-5.	0.5	5
178	Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, S478-S478.	0.9	5
179	Genomic characterization of recurrent mold infections in thoracic transplant recipients. Transplant Infectious Disease, 2018, 20, e12935.	1.7	5
180	1758. Epidemiology of Invasive Mycoplasma and Ureaplasma Infections Early after Lung Transplantation. Open Forum Infectious Diseases, 2019, 6, S646-S646.	0.9	5

#	Article	IF	Citations
181	The History of Cryptococcus and Cryptococcosis. , 0, , 17-26.		5
182	Diagnostic Approach Based on Capsular Antigen, Capsule Detection, Î²-Glucan, and DNA Analysis. , 0, , 547-564.		5
183	Population Structure and Ecology of Cryptococcus neoformans and Cryptococcus gattii. , 0, , 97-111.		5
184	Antifungal resistance: the clinical front. Oncology, 2004, 18, 15-22.	0.5	5
185	Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement. Journal of Fungi (Basel, Switzerland), 2022, 8, 212.	3.5	5
186	Efficient, Cost-Effective, High-Throughput, Multilocus Sequencing Typing (MLST) Method, NGMLST, and the Analytical Software Program MLSTEZ. Methods in Molecular Biology, 2017, 1492, 197-202.	0.9	4
187	Feasibility of Neurapheresisâ„¢ as a Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis. Open Forum Infectious Diseases, 2017, 4, S480-S481.	0.9	4
188	Paediatric bacterial meningitis in the USA: outcomes and healthcare resource utilization of nosocomial versus community-acquired infection. Journal of Medical Microbiology, 2021, 70, .	1.8	4
189	Drug Resistance in Cryptococcosis. , 2017, , 1119-1140.		4
190	Biosynthesis and Genetics of the Cryptococcus Capsule. , 0, , 27-41.		4
191	Cryptococcosis in AIDS. , 0, , 515-525.		4
192	The Cell Wall of Cryptococcus. , 0, , 67-79.		4
193	Prevention of Human Infection. , 0, , 519-530.		4
194	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). Contemporary Clinical Trials Communications, 2021, 24, 100851.	1.1	4
195	What Can the Clinical Mycology Laboratory Do for Clinicians Today and Tomorrow?. Current Clinical Microbiology Reports, 2017, 4, 96-105.	3.4	3
196	QTc Prolongation in Patients Receiving Triazoles and Amiodarone. Open Forum Infectious Diseases, 2017, 4, S84-S84.	0.9	3
197	A Novel Therapeutic Approach for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2016, 3, .	0.9	3
198	A Role for Mating in Cryptococcal Virulence. , 0, , 167-174.		3

#	Article	IF	Citations
199	Drug Resistance in Cryptococcus: Epidemiology and Molecular Mechanisms. , 0, , 203-216.		3
200	Cryptococcosis in Africa. , 0, , 269-285.		3
201	Cryptococcosis in Asia. , 0, , 287-297.		3
202	The Emergence of Cryptococcus gattii Infections on Vancouver Island and Expansion in the Pacific Northwest. , 0, , 313-325.		3
203	Melanin: Structure, Function, and Biosynthesis in Cryptococcus. , 0, , 55-66.		3
204	Sexual Reproduction of Cryptococcus. , 0, , 81-96.		3
205	Introduction to the Pathogen. , 0, , 1-27.		3
206	Therapy of Cryptococcosis. , 0, , 457-518.		3
207	Specific Immunity and Cytokines. , 0, , 223-269.		3
208	Curvularia alcornii Aortic Pseudoaneurysm Following Aortic Valve Replacement: Case Report and Review of the Literature. Open Forum Infectious Diseases, 2021, 8, ofab536.	0.9	3
209	Editorial Commentary: Life-saving Antimicrobial Drugs: What Are We Doing to Pricing and Availability?. Clinical Infectious Diseases, 2016, 62, 1569-1570.	5.8	2
210	In Vitro Characterization of the Neurapheresisâ„¢ System for the Treatment of Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, S481-S481.	0.9	2
211	On-demand release of Candida albicans biofilms from urinary catheters by mechanical surface deformation. Biofouling, 2018, 34, 595-604.	2.2	2
212	Sensing Extracellular Signals in Cryptococcus neoformans. , 0, , 175-187.		2
213	Signaling Cascades and Enzymes as Cryptococcus Virulence Factors. , 0, , 217-234.		2
214	Sexual Reproduction of Cryptococcus gattii: a Population Genetics Perspective. , 0, , 299-311.		2
215	Hybridization and Its Importance in the Cryptococcus Species Complex. , 0, , 359-370.		2
216	Cryptococcosis in Experimental Animals: Lessons Learned. , 0, , 473-488.		2

#	Article	IF	Citations
217	Management of invasive mycoses in hematology patients: current approaches. Oncology, 2004, 18, 5-14.	0.5	2
218	OUP accepted manuscript. Medical Mycology, 2022, , .	0.7	2
219	Transcriptional Profiles Elucidate Differential Host Responses to Infection with Cryptococcus neoformans and Cryptococcus gattii. Journal of Fungi (Basel, Switzerland), 2022, 8, 430.	3.5	2
220	IRIS and Fungal Infections: What Have We Learned?. Current Fungal Infection Reports, 2012, 6, 1-10.	2.6	1
221	Reply to ArgÃ¼elles. Virulence, 2017, 8, 239-239.	4.4	1
222	Curious Crosses: Injection-Induced Lesions. American Journal of Medicine, 2017, 130, 31-33.	1.5	1
223	Invasive Fungal Disease in the Transplant Population: An Overview. , 2019, , 519-541.		1
224	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27â€“30, 2018, Big Sky, Montana, a proposed global research agenda. Medical Mycology, 2020, 58, 569-578.	0.7	1
225	Black mold takes hold and story told. Medical Mycology Case Reports, 2020, 29, 12-14.	1.3	1
226	Outcomes and Health Care Resource Utilization of Adult Bacterial Meningitis in the United States. Neurology: Clinical Practice, 2021, 11, 117-126.	1.6	1
227	Reply to Day et al. Journal of Infectious Diseases, 2021, 224, 1627-1628.	4.0	1
228	Cryptococcus Interactions with Innate Cytotoxic Lymphocytes. , 0, , 417-427.		1
229	Cryptococcosis in Transplant Recipients. , 0, , 505-514.		1
230	Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma. , 0, , 537-546.		1
231	Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.. Blood, 2006, 108, 3311-3311.	1.4	1
232	Antifungal pharmacotherapy for invasive mould infections. Expert Opinion on Pharmacotherapy, 2003, 4, 147-164.	1.8	1
233	G-Protein Signaling Pathways: Regulating Morphogenesis and Virulence of Cryptococcus. , 0, , 151-165.		1
234	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries. , 0, , 565-584.		1

#	Article	IF	Citations
235	Animal Models and Veterinary Aspects of Cryptococcosis. , 0, , 325-350.		1
236	Intracellular Replication and Exit Strategies. , 0, , 441-450.		1
237	Use of newer antifungal therapies in clinical practice: what do the data tell us?. Oncology, 2004, 18, 15-23.	0.5	1
238	Future strategies for the treatment of cryptococcal meningoencephalitis in pediatric patients. Expert Opinion on Orphan Drugs, 2014, 2, 245-257.	0.8	0
239	On-Demand Release of Candida albicans Biofilms From Urinary Catheters by Mechanical Surface Deformation. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
240	Identification of Host-Derived Biomarker Signatures in Cryptococcal Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
241	Dosing Voriconazole in Obese Patients. Open Forum Infectious Diseases, 2017, 4, S292-S293.	0.9	0
242	2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes. Open Forum Infectious Diseases, 2019, 6, S715-S715.	0.9	0
243	Fungal Infections of the Central Nervous System. , 2021, , 803-819.		0
244	Tissue Responses and Special Topics in Immunity. , 0, , 271-324.		0
245	Virulence Mechanisms of Cryptococcus gattii: Convergence and Divergence. , 0, , 189-201.		0
246	Acquired Humoral Immunity to Cryptococcus neoformans. , 0, , 397-408.		0
247	The Interaction of Cryptococcus neoformans with Host MacroPhages and Neutrophils. , 0, , 371-385.		0
248	Pulmonary Innate and Adaptive Defenses against Cryptococcus. , 0, , 451-464.		0
249	Physical Defenses and Nonspecific Immunity. , 0, , 177-222.		0
250	Management of phaeohyphomycosis. , 2019, , 337-345.		0
251	Management of mucormycoses. , 2019, , 357-362.		0
252	Management of cryptococcosis. , 2019, , 301-315.		0

#	Article	IF	Citations
253	168. Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis. Open Forum Infectious Diseases, 2020, 7, S213-S213.	0.9	0